Prosecution Insights
Last updated: November 11, 2026
Application No. 18/833,506

6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS

Non-Final OA §112
Filed
Jul 26, 2024
Priority
Feb 25, 2022 — provisional 63/313,916 +2 more
Examiner
WELLS, LAUREN QUINLAN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Recludix Pharma Inc.
OA Round
1 (Non-Final)
49%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
128 granted / 259 resolved
-10.6% vs TC avg
Strong +60% interview lift
Without
With
+60.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
87 currently pending
Career history
348
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
36.0%
-4.0% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 259 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The amendment filed 08/26/2026, amended claims 1-50 and added claim 51. Claims 1-51 are pending. Priority This application claims the following priority: PNG media_image1.png 75 483 media_image1.png Greyscale Election/Restrictions Applicant’s election without traverse of Group I and Compound 395 in the reply filed on 08/26/2026, is acknowledged. In the course of the search, the entire genus of instant Formula (I) was searched. However, the election of species requirement is not withdrawn because it not clear if the compounds of instant claim 48 are species of instant Formula (I). See the below 112(b) rejection. Claim 50 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-49 and 51 are examined on the merits herein. Claim Objections Claim 10 is objected to because of the following informalities: -In claim 10, Formula (VII), a line indicating a bond between N and R8 is missing. Formula (VII) should be amended to properly depict the bond between N and R8. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-49 and 51 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. -In claim 1, pg., 8 of the claim set, in the definition of R8, it is not clear if “the phenyl” on line 12, is referencing “phenyl” in line 8 or “phenyl” in line 10, or both “phenyl” recitations in lines 8 and 10. -In claim 1, pg. 8 of the claim set, the last line of the page recites a definition of variable “AA” However, neither instant Formula (I) nor the R groups that further define Formula (I), recite variable “AA.” As such, it is not clear what “AA” is referencing. -Claim 48 recites “A compound selected from Compound 1 to 441,” which renders the claim indefinite since claim 48 contains zero compounds. It appears that claim 48 may be referencing Table 14 and other exemplified compounds in the specification, which is improper; "Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table 'is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant’s convenience.' Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993)" (MPEP 2173.05(s)). Thus, the metes and bounds of claim 48 are unascertainable. All other claims not specifically recited are rejected for depending from an indefinite claim and failing to cure the deficiency. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 25, 32-35 and 46 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. -Claim 25 depends from claim 1 and recites “(C1-C4) alkyl” as a member of the RY Markush group. However, claim 1 does not recite “(C1-C4) alkyl” as a member of the RY Markush group. -Claims 32-35 depend from claim 1 and recite “halo(C1-C4)alkyl” as a member of the RQ Markush group. However, claim 1 does not recite “halo(C1-C4)alkyl” as a member of the RQ Markush group. It is noted that RQ does recite a (C1-C4) alkyl group that can be substituted with 1-3 RM, wherein RM can be halo. However, the general recitation of “halo(C1-C4)alkyl” is outside the scope of the combination of RQ and RM as recited in claims 32-35. -Claim 46 depends from claim 45, which depends from 1, and recites “–(C1-C4)alkyl-[5-to 10-membered monocyclic or bicyclic heteroaryl” as a member of the R8 Markush group. However, claim 1 does not recite a “–(C1-C4)alkyl-[5-to 10-membered monocyclic or bicyclic heteroaryl” as a member of the R8 Markush group. -Claim 46 depends from claim 45, which depends from 1, and recites “–(C1-C4)alkyl-[5-to 6-membered heteroaryl” as a member of the RHa Markush group. However, claim 1 does not recite a “–(C1-C4)alkyl-[5-to 6-membered heteroaryl” as a member of the RHa Markush group. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Free of the Prior Art Claims 1-47 and 49 are free of the prior art. Due to the indefiniteness of claim 48, it is not known if claims 48 and 51 are free of the prior art. The closest prior art is WO 2021/195481 (IDS of 11/14/2024) which teaches: PNG media_image2.png 105 198 media_image2.png Greyscale as “Intermediate X” (pg. 195), and meets the limitations of instant formula I when: R1 is a 9-membered fused bicyclic heteroaryl substituted with CR1aR2aP(O)OR1bOR2b, wherein R1a and R2a are fluoro, R1b is H, and R2b is a C2 alkyl, R2-R6, are H, and p, q, and t are 1. However, ‘481 teaches R7 as a C3 alkyl substituted with S(O)2NH2 and C(O)OH, wherein S(O)2NH2 is outside the scope of the definition of instant R7. Moreover, there is no motivation to modify the intermediate of ‘481 to arrive at instant Formula (I) since the compound of WO 2021/195481 is an intermediate. As such, claims 1-47 and 49 are free of the prior art. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN WELLS whose telephone number is (571)272-7316. The examiner can normally be reached M-F 7:00-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Jim) Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAUREN WELLS/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jul 26, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778909
Composition Including Benzylaminoethanol Derivative as Active Ingredient for Prevention or Treatment of Metabolic Disease
2y 9m to grant Granted Nov 03, 2026
Patent 12766154
URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES
3y 3m to grant Granted Oct 20, 2026
Patent 12758564
METHODS AND MATERIALS FOR INHIBITING CB1 ACTIVITY
3y 7m to grant Granted Oct 13, 2026
Patent 12758528
COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES
3y 7m to grant Granted Oct 13, 2026
Patent 12746255
METHODS FOR IDENTIFYING PRE-DISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR IMPROVING COGNITIVE ABILITY
6y 11m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
49%
Grant Probability
99%
With Interview (+60.1%)
3y 0m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 259 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month